CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Hormone therapy or chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03556904
NCT03556904Phase 2Completed
CompareCT.gov

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE): A Phase II Randomized Trial

University of Michigan Rogel Cancer Center·interventional·Posted Jun 14, 2018·Updated Jan 15, 2026

In Brief

A Phase 2 clinical trial evaluating Ablative Radiation Therapy and Hormone therapy or chemotherapy for Prostate Cancer. Completed, enrolled 14 participants across 2 sites.

Detailed Summary

This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic castration-resistant prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 14, 2018
Enrollment StartDec 10, 2018
Primary CompletionJul 28, 2023
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.0 years ago

Interventions

Ablative Radiation Therapyradiation

Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.

Hormone therapy or chemotherapydrug

Current standard of care dosing with standard agents; hormone therapy or chemotherapy.